JOIN this TEC Validation Project™: New alternative to animal testing in human cardiac muscle cells

Together with Axiogenesis, we are excited to announce a new, free opportunity for drug safety professionals in the pharmaceutical industry. This unique opportunity will provide participants with the benefit of assessing, in a pre-competitive manner, a novel and disruptive safety technology, which could further optimize internal drug development processes.

Axiogenesis has developed a cost-effective, translational alternative for evaluating toxicity in human cardiac muscle cells very early during compound series selection. They have developed Cor.4U® human cardiomyocytes, derived from Induced Pluripotent Stem Cells (IPSCs), ‘non-controversial’ stem cells generated from adult somatic cells. Cor.4U Cardiomyocytes have a variety of applications, including being used to prioritize compound series before SAR by measuring characteristics such as beat rate, amplitude and more.

Axiogenesis has also developed an impedance assay, called CardioEffect, which applies Cor.4U cardiomyocytes to predictively assess cardiotoxicity more quickly and cost-effectively than common in vivo assays.

Interested in getting involved in this TEC Validation Project™ with the SafeTEC Consortium?

We are seeking new Biotech & Pharma corporate members for the SafeTEC consortium, along with others involved in pre-clinical safety testing for small molecules.

• Axiogenesis is hosting a webinar for members to discuss the cells, assays, a Large Pharma case study, and the needs of the drug discovery & development community.
• Axiogenesis will provide sufficient cells for the project. The assay will be repeated and blinded at one of our Consortium member sites.
• These results will be compared to in vivo/clinical data and discussed amongst Consortium members.

Who should join the Webinar and TEC Validation Project™?

• Medicinal Chemists seeking early feedback on the potential cardiotoxicity of chemical series
• Biologists and Assay Developers supporting Med Chem during Lead Selection
• Toxicology and Safety Researchers
• Senior Managers in early drug discovery